A grande procura da humanidade por meios que favoreçam uma vida saudável tem impulsionado as pesquisas por novas substâncias capazes de satisfazer tais necessidades, e entre estas substâncias encontram-se os fitoestrógenos. Processos biológicos relacionados a Doenças Cardiovasculares (DCV) e outras doenças podem ser afetados por essas substâncias presentes em plantas. O fitoestrógeno resveratrol é um polifenol especialmente encontrado na uva e seus derivados, e sua ingestão tem sido associada à baixa taxa de mortalidade por câncer e DCV. Os fitoestrógenos das plantas possuem semelhança estrutural e funcional com o estrógeno, com propriedades que beneficiam o metabolismo celular através de ação antioxidante e antiagregante plaquetária. O endotélio é o principal alvo da ação dos estrógenos. Eles promovem a redução do engrossamento da parede vascular, aceleram o processo de reconstrução do endotélio após injúria vascular e favorecem a angiogênese. Os estrógenos diminuem a expressão de moléculas de adesão em resposta à citocinas e possuem efeito anti-apoptótico nas células endoteliais. Polifenóis são fitoestrógenos com alto potencial antioxidante presentes em frutas, grãos, vegetais, nozes e raízes. Estes compostos vêm sendo amplamente estudados por seus efeitos na supressão de tumores e na prevenção de DCV em modelos animais. Neste estudo, temos como objetivo geral avaliar a ação do resveratrol na produção de óxido nítrico e prostaglandina E2 em modelo in vitro de células endoteliais da linhagem ECV 304, bem como atividade antioxidante. O objetivo específico é determinar a melhor concentração do resveratrol em que se observa uma potente liberação de substâncias vasoativas e maior proteção contra radicais livres, conferindo proteção e prevenção de DCV. / The vast search of humanity for ways that favors a healthy life has driven the researches for substances capable of meeting such needs, and among these substances there are the phytoestrogens. Biological processes related to Cardiovascular Disease (CVD) and other illness can be affected by these substances present in plants. The phytoestrogen resveratrol is a polyphenol specially found in grapes and derivates, and its ingestion has been associated to low mortality rates by cancer and CVD. The plants phytoestrogens are similar structurally and functionally with estrogens, with properties that benefit cellular metabolism through their antioxidant and antiplatelet action. The endothelium is estrogen´s major target. They reduce thickening of the vascular wall, accelerate the reconstruction process of vascular endothelial after injury and promote angiogenesis. The estrogens decrease the expression of adhesion molecules in response to cytokines and have antiapoptotic effect on endothelial cells, and promotes raising in nitric oxide (NO) production. Polyphenols are phytoestrogens with high antioxidant effect present in fruits, grains, vegetables, nuts and roots. These compounds have been extensively studied due to their effect on tumors suppression and CVD prevention in animal models. In this study, we evaluated resveratrol´s action in nitric oxide production and prostaglandin E2 in in vitro model of endothelial cells ECV304, as well as it´s antioxidant activity. The specific objective is to determine the best concentration of resveratrol in which observes a potent liberation of vasoactive factors and the best anti free radical activity, leading to protection and prevention of CVD.

Conselho Nacional de Desenvolvimento Científico e Tecnológico / Methylmalonic acidemias comprehend a group of innate error of the metabolism (EIM)characterized clinically and biochemically for the tissue accumulation of acid methylmalonic (MMA)and neurological dysfunction, including seizures. The clinical experience suggests that infections precipitate metabolic crises in methylmalonic acidemic patients. Since it has been demonstrated that MMA cause seizures, and that inflammation facilitates the occurrence of seizures in some animal models, is possible that inflammatory mediators, such as the prostaglandins, also facilitate MMAinduced seizures. Ciclooxigenase (COX) is the rate-limiting enzyme in the metabolic route by which the arachidonic acid is converted to prostaglandins. COX-2 is an isoform of cicloooxigenase that is induced at sites of injury / inflammation, and that is also constitutively expressed in some tissues, such as the central nervous system (CNS). It has been suggested that prostaglandin E2 (PGE2), the main product of COX-2 in the CNS, plays an important role in some neurodegenerative diseases, including epilepsy. However, no study has evaluated whether inflammatory mediators, such as the PGE2, facilitates MMA-induced seizures, to date. Thus, in this study we investigated the role of COX-2 and of PGE2 in seizures induced by MMA (2,5 µmol/2,5 µL, i.c.v.). While PGE2 (100 ng/2 μL, i.c.v.) facilitated, the selective COX-2 inhibitor celecoxib, attenuated MMA-induced seizures, assessed by electroencephalographic recordings in the hippocampus and cerebral cortex of rats. The ´protective effect of celecoxib against MMA-induced seizures was prevented by the PGE2. The results of this study support a facilitatory role for COX-2/PGE2 pathway in the MMA-induced seizures. / A acidemia metilmalônica é um erro inato do metabolismo (EIM) caracterizado bioquimicamente e clinicamente pelo acúmulo tecidual de ácido metilmalônico (MMA) e disfunção neurológica, que inclui convulsões. A experiência clínica sugere que infecções precipitam crises metabólicas em pacientes metilmalonicacidêmicos. À medida em que foi demonstrado que o MMA causa convulsões, e que a inflamação pode contribuir para a ocorrência de convulsões em vários modelos animais, é possível que mediadores inflamatórios, como as prostaglandinas, facilitem as convulsões induzidas por MMA. A ciclooxigenase (COX) é a enzima marca-passo na rota metabólica pela qual o ácido araquidônico é convertido em prostaglandinas, e a COX-2 uma isoforma da cicloooxigenase, é induzida em sítios de lesão/inflamação, e também se expressa constituivamente em alguns tecidos, como o sistema nervoso central (SNC). Tem sido sugerido que a prostaglandina E2 (PGE2), principal produto da via COX-2 no SNC, tenha um papel importante em várias doenças neurodegenerativas, incluindo epilepsia. Contudo, até a presente data nenhum estudo avaliou se mediadores inflamatórios, como a PGE2, facilitam as convulsões induzidas por MMA. Assim, neste estudo investigamos o papel da COX-2 e da PGE2 nas convulsões induzidas por MMA (2,5 µmol/2,5 µL, i.c.v.). Verificamos que a PGE2 (100 ng/2 μL, i.c.v.) facilita as convulsões induzidas por este ácido orgânico. Além disso, verificamos que o celecoxibe, um inibidor seletivo da COX-2, na dose de 2 mg/kg (v.o.), atenuou as convulsões comportamentais e eletrográficas induzidas por MMA no hipocampo e córtex cerebral de ratos. O efeito protetor do celecoxibe contra as convulsões induzidas por MMA foi revertido pela administração i.c.v. de prostaglandina E2. O conjunto de dados deste estudo suporta um papel facilitatório para a via COX-2/PGE2 nas convulsões induzidas por MMA.

Increases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.

Abstract Febrile seizures (FS) occur in 2-5% of children. Their pathogenesis is unknown. Elevated levels of prostaglandins (PG) have been found in cerebrospinal fluid after such seizures, and a third of all patients have recurrences. No safe ways of reducing the risk of recurrences have been found. The outcome has been shown in prospective studies to be good, by they have been linked to mesial temporal sclerosis (MTS) in patients with severe temporal lobe epilepsy (TLE). The aim was to analyze the records on the role of PGs in the pathogenesis of FS, to find risk factors for recurrences that are amenable to intervention and to evaluate the prevention of recurrences and the connection of FSs with MTS. We performed a systematic review of the effect of PGs and their synthetase inhibitors on seizures and a meta-analysis of the prevention of recurrences. The prophylactic effect of diazepam and acetaminophen on recurrences was evaluated in a placebo-controlled trial with 180 FS patients, and risk factors for recurrences were analysed from these data. To find MTS, MRI volumetry was performed after 12 years of follow-up on 64 cases chosen out of 329 unselected FS patients: twenty-four with a prolonged initial seizure, eight with a later unprovoked seizure and 32 age, sex and handedness-matched controls. PGD2, PGE1 and PGE2 had mainly anticonvulsive effects and PGF2alfa proconvulsive ones. NSAIDs had seizure-modulating effects in adult animals ranging from attenuation to provocation. Each degree of increase in fever doubled the recurrence risk, and each febrile episode increased it by 18%. The meta-analysis showed phenobarbital and valproate to prevent recurrences, but they cannot be recommended for FS as they have severe side-effects. The meta-analysis nullified the alleged effect of diazepam, and neither this nor acetaminophen prevented recurrences in a clinical trial. No MTS was found in any patient group. PGs may be involved in the pathogenesis of FS. No safe prophylaxis for recurrences is available, although the effect of antipyretics needs further evaluation. Measures to reduce feverish infections in order to prevent FS recurrences seem logical. MTS is uncommon even after prolonged FS.

Prostaglandin E2 (PGE2), a metabolite of arachidonic acid, plays a role in water and sodium reabsorption in the collecting duct of the kidney. The collecting duct is responsible for the fine tuning of water and electrolytes. Only a small fraction of the filtered water and sodium is reabsorbed in the collecting duct, a fraction crucial to the regulation of water and electrolyte balance. This current study addresses the role of EP1, one of four PGE2 receptors, in the collecting duct. It is well documented that PGE2 inhibits sodium and water reabsorption in the collecting duct, however the exact mechanism is still debated. To determine whether the EP1 receptor mitigates AngII renal effects, an in vivo study was performed with EP1-/- mice. Global EP1-/- knockout mice were crossed with a renin overexpressing mouse line (herein denoted as “Ren”) and subjected to a high salt (HS) and low salt (LS) diet. Ren mice displayed an 11mmHg increase in systolic blood pressure (BP) on a HS diet and a decrease in BP of 14mmHg on a LS diet compared to the normal salt (NS) diet. Ren EP1-/- mice did not display a significant increase or decrease in BP on a HS or LS diet. On a LS diet, Ren EP1-/- displayed a drop in urine osmolarity (1641 mOsm/ kgH2O) vs. wild type (WT) mice (2107 mOsm/ kgH2O), consistent with increased sodium reabsorption. Narrowing in on the collecting duct, Ren EP1-/- mice had enhanced αENaC levels compared to Ren mice. In ex vivo microperfusion experiments, EP1-/- tubules show no response to PGE2 in the presence of AVP, whereas PGE2 inhibits AVP induced water reabsorption in WT mice. An increase in αENaC membrane accumulation due to EP1 gene ablation results in increased sodium reabsorption subsequently leading to a rise in BP. This contributes to the lack of salt sensitivity in EP1-/- mice. Overall, the EP1 receptor in the collecting duct represents a potential therapeutic target for the treatment of hypertension.

La détermination du sexe et la différenciation des cellules germinales est un processus très organisé qui commence au stade embryonnaire et se termine à la vie adulte. Dans les gonades embryonnaires l'expression de Sry suivie par l'expression de Sox9 initie le développement testiculaire tandis que, en l'absence de l'expression de Sry, les gènes associés au sexe féminin initient le développement des ovaires. Les cellules germinales qui ont migré vers les gonades nouvellement formées continuent leur prolifération intense jusqu'à ce qu'ils s'engagent dans la voie le mâle ou femelle. La décision de devenir des cellules germinales mâle ou femelle ne dépend pas seulement du chromosome sexuel des cellules germinales, mais aussi du microenvironnement des gonades. Si les cellules germinales entrent dans la gonade femelle, ils doivent arrêter la prolifération, dépasser l'arrêt mitotique et entrer en méiose et alors s'arrêter en prophase I. Alors que si les cellules germinales entrent dans la gonade mâle, ils doivent arrêter la prolifération et entrer en arrêt de la mitose. Ici, nous montrons que, lors de la détermination du sexe embryonnaire, la prostaglandine D2 (PGD2) produite par chacune des deux enzymes: la L-PGDS et H-PGDS dans les cellules somatiques et les cellules germinales du testicule mâle participe au programme de différenciation des cellules germinales. La voie de signalisation PGD2 entraine l'arrêt de la mitose par l'activation de l'expression et de la localisation nucléaire de l'inhibiteur du cycle cellulaire p21Cip1 et en réprimant les marqueurs de pluripotence et aussi Stra8. En outre, PGD2 est responsable de l'activation du gène spécifique au mâle Nanos2. Par conséquent, ces données suggèrent que la signalisation par le récepteur de PGD2 DP2 est requise pour la différenciation correcte de la cellule germinale mâle. / The sex determination and subsequent germ cell differentiation is highly ordered process that starts at embryonic stage and completes at adult life. In the embryonic gonads Sry expression followed by Sox9 expression initiates testis development while in the absence of Sry expression, genes associated to female fate initiate ovary development. The germ cells that migrated towards newly formed gonads continue extensive proliferation until they commit to the male or female pathway. The fate decision of germ cells as male or female does not depend only on germ cell chromosomal sex but also on gonadal micro-environment. If germ cells enter into female gonad, they have to stop proliferation, pass through mitotic arrest and enter into meiosis; then arrest into prophase I. While if germ cells enter into male gonad, they have to stop proliferation and enter into mitotic arrest. Here we show that during embryonic sex determination, Prostaglandin D2 (PGD2) produced by each of the two enzymes: L-Pgds and H-Pgds in somatic cells and germ cells of testis participates in male germ cell differentiation program. PGD2 signalling supports mitotic arrest by activating the expression and nuclear localization of cell cycle inhibitor P21cip1 and by repressing pluripotency markers and PGD2 has negative effects on Stra8 expression. In addition PGD2 supports activation of male specific gene Nanos2. Hence these data suggest that PGD2 signalling through DP2 receptor is required for proper male germ cell differentiation.

The World Health Organization classifies glioblastoma (GBM) as a type IV astrocytoma, making it one of the most fatal tumors that exists. Despite the advances in chemotherapy, surgery, and radiation treatments that improve a patients length of survival, the overall trajectory of the disease remains unchanged. It has been shown that GBM cells produce significant levels of prostaglandins, including prostaglandin D2 (PGD2). PGD2 possesses pro- and anti-tumorigenic properties. Hence, a more complete understanding of PGD2 activity in GBM could yield more effective treatments against GBM. Through techniques like RT-PCR, immunohistochemistry, and HPLC tandem mass spectrometry, we were able to confirm the presence of the PGD2 synthesis in GBM cell lines. We treated GBM cell lines with various concentrations of exogenous PGD2 over 72 hours and observed its effects on cell count, apoptosis, mitosis and viability. Our results suggest that PGD2 possesses contradictory functions in GBM depending on concentration (mM PGD2 vs. nM PGD2) and receptor activation. / A Organização Mundial de Saúde classifica glioblastoma (GBM) como um astrocitoma tipo IV, fazendo uns dos tumores mais fatais que existe. A pesar dos avanços em quimioterapia, cirurgia e radioterapia que melhoram a longevidade de sobrevivência, a trajetória geral da doença permanece imutável. Tem sido demonstrado que células de GBM produzem níveis significativos de prostaglandinas, incluindo prostaglandina D2 (PGD2). PGD2 possui propriedades pro- e anti-tumorigenicos. Então, um entendimento mais completo da atividade de PGD2 em GBM pode gerar tratamentos mais efetivos. Através de técnicas como RT-PCR, imunohistoquimicas e HPLC espectrometria de massa em tandem, conseguimos confirmar a presença da síntese de PGD2 em linhagens de GBM. Tratamos linhagens de GBM com concentrações variáveis de PGD2 exógeno durante 72 horas e observamos seus efeitos na contagem de células, apoptose, mitose e viabilidade. Nossos resultados sugerem que PGD2 possui funções opostas em GBM dependendo em concentração (mM PGD2 vs. nM PGD2) e ativação de receptores.

Made available in DSpace on 2016-05-02T13:55:51Z (GMT). No. of bitstreams: 1 LeandroBecaleteRizzoni-Dissertacao.pdf: 3096648 bytes, checksum: d5c52567fe33e15db0244070559133db (MD5) Previous issue date: 2012-04-18 / This study assessed the of effects the application of cloprostenol in postpartum dairy goats. Twenty-nine Anglonubian goats were used, evenly divided into two groups. The control group received 0.5 ml of saline (0.9%) and group PGF2 0.133 mg cloprostenol in two intramuscular applications on day 1 (D1) and four (D4) PP. The reproductive tract of the animals was assessed by transrectal ultrasound with a linear, 5.0 MHz on days 1, 4, 10, 16, 22, 28, 34, 40 and 46 postpartum. The uterine diameter, cervical diameter, volume of the intrauterine contents and uterine position were measured. In four animals from each treatment the endometrial thickness and diameter of the two larger follicles present in the ovary were evaluated, and vaginoscopy revealed the presence and aspect of the cervical mucus. The data were tested using the ANOVA analysis of variance and the averages (uterine diameter and endometrial thickness), by the Tukey test. The position of the uterus was assessed by the X2 test (chi-square). The body condition score and volume of intrauterine contents were evaluated with the nonparametric Wilcoxon test. All parameters were considered significant at 5% probability level. The uterine diameter behaved differently between the groups. In the PGF2 group there was a marked reduction in uterine diameter until day 22 PP (3.5 ± 0.6 cm) and the control group until day 28 PP (3.6 ± 0.8 cm). The expulsion of uterine contents was earlier in PGF2 group (D40), and on D46 in the control group. Likewise, the presence of cervical mucus was earlier in PGF2 group (D34) compared to control group (D40). The follicular growth did not differ between the groups, the maximum average diameters were 5.1 ± 0.3 mm at 28 dpp for the PGF2 group and 5.2 ± 0.4 mm at 22 dpp for the control group. The results suggest that cloprostenol acts beneficially in the process of uterine involution and expulsion of uterine contents. Key-words: Goats, Uterine involution, Prostaglandin. / Objetivou-se verificar os efeitos da aplicação do cloprostenol sódico no puerpério de cabras leiteiras. Utilizaram-se vinte e nove cabras Anglonubianas, divididas uniformemente em dois grupos. O grupo controle recebeu 0,5 mL de solução salina (0,9%) e o grupo PGF2 0,133 mg de cloprostenol sódico em duas aplicações, nos dias 1 (D1) e 4 (D4) PP, pela via intramuscular. O aparelho reprodutivo dos animais foi avaliado através de ultrassonografia transretal, com transdutor linear de 5.0 MHz nos dias 1, 4, 10, 16, 22, 28, 34, 40 e 46 pós-parto. Aferiu-se o diâmetro uterino, diâmetro cervical, posição uterina e volume do conteúdo intrauterino. Em quatro animais de cada tratamento avaliou-se a espessura do endométrio e diâmetro dos dois maiores folículos presentes nos ovários e, através da vaginoscopia, observou-se a presença e aspecto do muco cervical. Os dados foram submetidos ao teste de analise de variância ANOVA e as médias (diâmetro uterino e espessura do endométrio) ao teste de Tukey. Para a posição uterina, utilizou-se o teste X2 (Qui-quadrado). Para o escore de condição corporal e volume de conteúdo intrauterino procedeu-se ao teste não paramétrico de Wilcoxon. Todas as variáveis foram consideradas significativas a 5% de probabilidade. O diâmetro uterino se comportou de maneira diferente entre os grupos. No grupo PGF2houve uma acentuada redução do diâmetro uterino até o dia 22 PP (3,5 ± 0,6 cm) e no grupo controle, até o dia 28 PP (3,6 ± 0,8 cm). A expulsão do conteúdo uterino foi anterior no grupo PGF2 (D40), enquanto para o grupo controle a expulsão completou-se no D46. Da mesma forma, a presença de muco cervical foi anterior no grupo PGF2(D34) quando comparado ao grupo controle (D40). O crescimento folicular não diferiu entre os grupos. Os diâmetros médios máximos observados foram de 5,1 ± 0,3 mm aos 28 dpp, para o grupo PGF2 e 5,2 ± 0,4 mm aos 22 dpp, para o grupo controle. Os resultados sugerem que o cloprostenol sódico atua beneficamente no processo de involução uterina e expulsão do conteúdo uterino.

In this study 272 beef heifers were studied from just prior to their first breeding season (15 October 2003), through their second breeding season and until just after they had weaned their first calves in March 2005. The study consisted of two main parts: in the first part, heifers were randomly allocated to either a synchronised TEST group or an unsynchronised CONTROL group. The TEST group received artificial insemination (AI) for 6 days followed by prostaglandin F2á (PGF) treatment on day 6 (PGF/6) and further AI for a total of 50 days, which was followed after a 6 day break by a 42 day bull breeding season. The CONTROL group were bred for the same period without PGF treatment. Synchronisation resulted in a reduction in days to first insemination (P < 0.01) and days to calving (P = 0.04). No significant difference could be demonstrated in pregnancy rate to the 50 day AI season (60.0% vs. 51.8%, TEST and CONTROL groups respectively, P = 0.18), final pregnancy rate (82.2% vs. 83.2%, P = 0.87) or pregnancy rate to the subsequent breeding season (96.0% vs. 95.0%, P = 1.00). A significant increase in mean weaning mass of the calves due to synchronisation could not be demonstrated (207.0 kg vs. 201.4 kg, TEST and CONTROL groups respectively, P = 0.32). However, data from this study were used to calculate the benefit:cost ratio, and a value of 2.8 was reached, representing the return on investment for the synchronisation protocol under these circumstances. It was concluded from this study that a PGF/6 protocol may lead to a change in the total mass of calves weaned by changing days to calving and thus weaning mass, birth mass of calves, weaning rate and/or the ratio of male:female calves born. It was further concluded that a practical way to predict the cost effectiveness of an oestrus synchronisation protocol is to determine the ratio between the total cost of the programme and the price of weaner calves per kg live mass. This ratio represents the minimum increase in mean weaning mass that has to be achieved for the programme to be cost effective if no increase in weaning rate is achieved. In the second part of this study, reproductive tract scoring (RTS) was performed on the same group of heifers one day before the onset of their first breeding season. The effect of RTS on several reproduction and production outcomes was tested, and the association of RTS with the outcomes was compared to the associations of other input variables such as mass, age, body condition score (BCS) and Kleiber ratio using multiple or univariable linear or logistic regression. RTS was associated with pregnancy rate to the 50 day AI season (P < 0.01), days to calving (r = 0.28, P < 0.01), calf weaning mass (r = 0.22, P < 0.01) and pregnancy rate to the subsequent breeding season (P < 0.01). These associations were mostly independent of associations with mass, age and BCS before the onset of the first breeding season. RTS was a better predictor of fertility than was Kleiber ratio, and similar in its prediction of calf weaning mass. It was concluded from this study that RTS is a unique predictor of heifer fertility, compares well with (but is independent of) other traits used as a predictor of production outcomes and is likely to be a good predictor of life production of the cow. / Dissertation (MSc (Veterinary Sciences))--University of Pretoria, 2006. / Production Animal Studies / unrestricted

The incidence of chronic kidney disease (CKD) is increasing. CKD is characterized by a gradual decrease in renal function leading to end stage renal disease (ESRD). Damage to the glomerular podocytes, is one of the first hallmarks of CKD. We hypothesized that podocyte prostaglandin E2 (PGE2) receptors contribute to the progression of glomerular injury in models of CKD. To test this hypothesis, transgenic mice were generated with either podocyte-specific overexpression or deletion of the PGE2 EP4 receptor (EP4pod+and EP4pod-/- respectively). Mice were next tested in the 5/6 nephrectomy (5/6 Nx) or angiotensin II (Ang II) models of CKD. These studies revealed increased proteinuria and decreased survival for EP4pod+ mice while EP4pod-/- mice were protected against the development of glomerular injury. Furthermore, our findings were supported by in vitro studies using cultured mouse podocytes where an adhesion defect was uncovered for cells overexpressing the EP4 receptor. Additionally, our investigations have demonstrated a novel synergy between angiotensin II AT1 receptors and prostaglandin E2 EP4 receptors. This was revealed by in vitro studies using isolated mouse glomeruli. There we were able to show that Ang II stimulation leads to increased expression of cyclooxygenase 2 (COX-2), the enzyme responsible for synthesis of PGE2, in a p38 mitogen activated protein kinase (MAPK) dependent fashion. Moreover increased PGE2 synthesis was measured in response to Ang II stimulation. We confirmed the presence of this synergy in our cultured mouse podocytes and showed an adhesion defect in response to Ang II stimulation which was COX-2 and EP4 dependent. These findings suggest that Ang II AT1 receptors and PGE2 EP4 receptors act in concert to exacerbate glomerulopathies. Studies using mice with either podocyte-specific overexpression of a dominant negative p38 MAPK or mice with global deletion of the EP1 receptor did not provide conclusive results as to their respective signaling involvement in podocyte injury. Altogether our findings provide novel insight for podocyte PGE2 EP4 and Ang II AT1 receptor signaling in models of CKD. These studies provide novel avenues for pursuing therapeutic interventions for individuals with progressive kidney disease.